Total population | 6 948 445 | 4 105 268 | 8 737 370 | 2 078 932 |
Number of new cancer cases (all cancer sites) | 36 451 | 26 092 | 49 043 | 14 180 |
Incidence age-standardized rate per 100 000 | 100 | 120.3 | 145.3 | 121.2 |
Number of new BC cases in 2020, both sexes, all ages | 4061 | 2894 | 6724a | 1410 |
BC new cases – rank across all types of cancers | 3 | 2 | 2 | 3 |
5-year prevalence, all ages (per 100 000) | 425.45 | 523.4 | 549.32 | 560.03 |
Mortality age-standardized rate per 100 000 | 36.3 | 32.8 | 50.9 | 32.3 |
Number of BC deaths | 1533 | 832 | 2342 | 405 |
BC deaths – rank across all types of cancers | 3 | 3 | 2 | 5 |
Mortality-to-incidence ratiob | 0.36 | 0.27 | 0.35 | 0.27 |
CDK4/6 inhibitors | 2018 | 2018 | 2022 | 2018 |
Alpelisib | 2023 | 2021 | 2023 | 2021 |
PARP inhibitors | 2023 | 2022 | 2021 | 2021 |
Sacituzumab govitecan | 2023 | 2022 | ||
Trastuzumab deruxtecan | 2022 | 2023 | ||
Atezolizumab nab-paclitaxel | 2022 | 2021 | 2020 | |
Pembrolizumab | 2023 |
2022 | 2023 | |
Everolimus | By >10 years | 2021 | 2010 | |
Fulvestrant | By >10 years | By >10 years | 2019 | 2004 |
Aromatase inhibitors | By >10 years | By >10 years | 2008 | By >20 years |